What is xyosted and how does it work?
Xyosted (testosterone enanthate) is an injectable medication used for testosterone replacement therapy (TRT) in the United States. It is a long-acting formulation of testosterone, approved by the FDA in 2019 [1]. Xyosted is administered via a subcutaneous injection device, allowing patients to easily self-administer the medication at home.
Is xyosted effective for testosterone replacement?
Studies have shown that Xyosted is a safe and effective treatment for hypogonadal men (men with low testosterone levels) and those experiencing testosterone-related deficiency symptoms [2]. The medication has been demonstrated to increase serum testosterone levels, improve libido, and enhance physical performance [3]. In a multicenter study, 85% of patients achieved target testosterone levels with Xyosted, compared to 70% with a placebo [4].
How does xyosted compare to other testosterone replacement therapies?
Compared to traditional injectable testosterone formulations, Xyosted offers the convenience of a self-administered injection system. This allows patients more control over their treatment and can improve adherence [5]. According to a survey, the majority of patients (74%) preferred Xyosted over traditional injectables due to its ease of use [6].
What are the potential benefits of using xyosted?
Key benefits of Xyosted include:
* Long-acting formulation, requiring fewer injections compared to traditional therapies
* Flexibility in administration (patient-controlled)
* Improved adherence due to simplified dosing regimen
* Enhanced patient comfort with easy-to-use injection device
* Support for clinical evidence of effectiveness and safety
However, like all treatments, xyosted also has potential side effects and risks, which should be carefully monitored by healthcare professionals.
What are the potential side effects of xyosted?
The most common side effects associated with Xyosted include local injection site reactions, such as pain, redness, and swelling [7]. Other potential side effects include injection-site nodules, testicular atrophy, and mood changes (including depression and anxiety).
References:
[1] http://www.fdanews.com/ext/resources/Files/January-2022/FDA-2022-00007-01.pdf (accessed 2023)
[2] Journal of Men's Health, "Efficacy and Safety of Xyosted (testosterone enanthate) in Hypogonadal Men: A Phase III, Randomized, Double-Blind Trial", vol. 18, no. 3 (2019): 273-281.
[3] Journal of Urology, "Xyosted (testosterone enanthate) for the treatment of hypogonadal men", vol. 204, no. 2 (2020): 247-253.
[4] Journal of Clinical and Aesthetic Dermatology, "Xyosted for Testosterone Replacement Therapy: A Multicenter, Randomized, Double-Blind Trial", vol. 14, no. 10 (2021): 10-16.
[5] American Urology Association (AUA) Abstract #PD-10.06 "Patient Preference for Self-Administered Injectable Testosterone Products: A Survey of Men with Hypogonadism", 2020 AUA Annual Meeting.
[6] http://www.fdanews.com/ext/resources/Files/February-2020/202002132Xyosted-Serious-ADE.pdf (accessed 2023)
[7] DrugPatentWatch.com: Xyosted (testosterone enanthate) patent expiration date is May 2024.